Compare Orchid Chemicals with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs AUROBINDO PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD AUROBINDO PHARMA ORCHID PHARMA LTD/
AUROBINDO PHARMA
 
P/E (TTM) x -0.5 10.3 - View Chart
P/BV x 0.1 1.9 6.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
AUROBINDO PHARMA
Mar-19
ORCHID PHARMA LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs194830 23.4%   
Low Rs35527 6.6%   
Sales per share (Unadj.) Rs276.5333.9 82.8%  
Earnings per share (Unadj.) Rs-79.240.4 -196.3%  
Cash flow per share (Unadj.) Rs-43.551.8 -84.0%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9237.1 22.8%  
Shares outstanding (eoy) m70.45585.91 12.0%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.42.0 20.4%   
Avg P/E ratio x-1.416.8 -8.6%  
P/CF ratio (eoy) x-2.613.1 -20.1%  
Price / Book Value ratio x2.12.9 74.2%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m8,067397,569 2.0%   
No. of employees `0002.817.9 15.7%   
Total wages/salary Rs m2,52725,849 9.8%   
Avg. sales/employee Rs Th6,956.110,956.9 63.5%   
Avg. wages/employee Rs Th902.51,447.7 62.3%   
Avg. net profit/employee Rs Th-1,993.01,324.3 -150.5%   
INCOME DATA
Net Sales Rs m19,477195,636 10.0%  
Other income Rs m4071,553 26.2%   
Total revenues Rs m19,884197,189 10.1%   
Gross profit Rs m1,10339,519 2.8%  
Depreciation Rs m2,5196,680 37.7%   
Interest Rs m5,2272,626 199.0%   
Profit before tax Rs m-6,23631,767 -19.6%   
Minority Interest Rs m2027 73.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-881 -58.0%   
Tax Rs m-1257,269 -1.7%   
Profit after tax Rs m-5,58023,645 -23.6%  
Gross profit margin %5.720.2 28.0%  
Effective tax rate %2.022.9 8.8%   
Net profit margin %-28.712.1 -237.1%  
BALANCE SHEET DATA
Current assets Rs m11,014153,645 7.2%   
Current liabilities Rs m32,060120,429 26.6%   
Net working cap to sales %-108.117.0 -636.4%  
Current ratio x0.31.3 26.9%  
Inventory Days Days95135 70.2%  
Debtors Days Days3464 52.7%  
Net fixed assets Rs m29,440103,909 28.3%   
Share capital Rs m705586 120.2%   
"Free" reserves Rs m2,043138,322 1.5%   
Net worth Rs m3,800138,908 2.7%   
Long term debt Rs m9,0181,800 501.1%   
Total assets Rs m46,510264,544 17.6%  
Interest coverage x-0.213.1 -1.5%   
Debt to equity ratio x2.40 18,319.3%  
Sales to assets ratio x0.40.7 56.6%   
Return on assets %-0.89.9 -7.7%  
Return on equity %-146.917.0 -862.7%  
Return on capital %-3.723.8 -15.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51397,316 7.7%   
Fx outflow Rs m5,64940,589 13.9%   
Net fx Rs m1,86556,727 3.3%   
CASH FLOW
From Operations Rs m1,68216,220 10.4%  
From Investments Rs m-9,860-28,768 34.3%  
From Financial Activity Rs m6,64419,191 34.6%  
Net Cashflow Rs m-1,5356,656 -23.1%  

Share Holding

Indian Promoters % 32.3 54.1 59.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.0 57.9%  
FIIs % 3.3 27.7 11.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.2 542.2%  
Shareholders   84,811 69,601 121.9%  
Pledged promoter(s) holding % 54.9 8.6 641.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  PROCTER & GAMBLE HEALTH  DISHMAN PHARMA  J.B.CHEMICALS  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Lower; Telecom and Metal Stocks Witness Selling(Closing)

Share markets in India continued to trade on a volatile note during closing hours and ended their trading session marginally lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

How We Made 14.64% Trading Profit in Just 2 Days

Dec 12, 2019

A high probability trade that worked to perfection for my subscribers.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

Stocks that Can Outperform No Matter what the RBI Does Today(The 5 Minute Wrapup)

Dec 5, 2019

I won't be surprised if these stocks repeat their 2002-2006 performance.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS